NCT03700294View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 21, 2018

Primary Completion Date

December 11, 2019

Study Completion Date

December 11, 2019

Conditions
Advanced Solid Tumors
Interventions
DRUG

ADCT-601

Intravenous (IV)

Trial Locations (4)

34232

Florida Cancer Specialists, Sarasota

37203

The Sarah Cannon Research Institute (Tennessee Oncology), Nashville

78240

NEXT Oncology, San Antonio

80218

Sarah Cannon Research Institute at HealthONE, Denver

Sponsors
All Listed Sponsors
lead

ADC Therapeutics S.A.

INDUSTRY